Journal of Integrative Oncology

ISSN: 2329-6771

Open Access

A Rare Case OF HER 2 Amplified and MET Mutated Metastatic Gastric Cancer with Clinical Benefit to MET Inhibition: A Case Report


Dr. Joydeep Ghosh

The treatment of metastatic stomach cancer has evolved over the last few years. Presently, the most common chemotherapy regimen comprises of Fluorouracil and platinum-based combinations. In the case of HER 2 positive disease, the treatment involves a combination of chemotherapy with trastuzumab. However, there have been cases of resistance to the above combination. Multiple underlying molecular mechanisms have been postulated for the resistance. One of the commonest pathways is CMET mutation. However, the presence of C MET and HER 2 is very rare. Here, we present such a rare case of metastatic stomach cancer who had abnormalities in both the pathways leading to resistance to Trastuzumab.


Share this article

Google Scholar citation report
Citations: 495

Journal of Integrative Oncology received 495 citations as per Google Scholar report

Journal of Integrative Oncology peer review process verified at publons

Indexed In

arrow_upward arrow_upward